Seroquel Evaluation On Improvement In Short And Long-Term Symptoms

AstraZeneca (NYSE:AZN) announced new study data on SEROQUEL XR? (quetiapine fumarate) Extended-Release Tablets (quetiapine XR) for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adult patients. The results from the studies were presented today at the 161st Annual Meeting of the American Psychiatric Association (APA) in Washington, DC.

More: continued here

Filed under: Anxiety on May 15th, 2008